NEW YORK – Commercial lab company OmniSeq on Thursday announced that it is collaborating with the University of Pittsburgh Medical Center (UPMC) on a Phase II clinical trial of immunotherapy in head and neck cancer.
NEW YORK – Commercial lab company OmniSeq on Thursday announced that it is collaborating with the University of Pittsburgh Medical Center (UPMC) on a Phase II clinical trial of immunotherapy in head and neck cancer.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.